Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2020 October;75(5) > Minerva Chirurgica 2020 October;75(5):328-44

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Chirurgica 2020 October;75(5):328-44

DOI: 10.23736/S0026-4733.20.08436-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

The actual management of colorectal liver metastases

Leticia PÉREZ-SANTIAGO 1, Dimitri DORCARATTO 1 , Marina GARCÉS-ALBIR 1, Elena MUÑOZ-FORNER 1, Marisol HUERTA ÁLVARO 2, Susana ROSELLÓ KERANËN 2, Luis SABATER 1

1 Unit of Liver, Biliary and Pancreatic Surgery, Department of Surgery, Clinic Hospital, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; 2 Department of Medical Oncology, Clinic Hospital, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain



Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease. There have been great improvements in the management of CRLM during the last decades. The combination of modern chemotherapeutic and biological systemic treatments with aggressive surgical resection strategies is currently the base for the treatment of patients considered unresectable until few years ago. Furthermore, several new treatments for the local control of CRLM have been developed and are now part of the arsenal of multidisciplinary teams for the treatment of these complex patients. The aim of this review was to summarize and update the management of CRLM, its controversies and relevant evidence.


KEY WORDS: Colorectal neoplasms; Neoplasm metastases, Drug therapy

top of page